Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-((1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
2. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
3. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-, Methanesulfonate (1:2)
4. D-824
5. D-824 Dimesylate
6. D824
7. Gzd-824
8. Gzd-824 Dimesylate
9. Gzd824
10. Hqp-1351
11. Hqp-1351 Dimesylate
12. Hqp1351
13. Hqp1351 Dimesylate
14. Olverembatinib
15. Olverembatinib Dimesylate
1. 1257628-77-5
2. Gzd824
3. Olverembatinib
4. Gzd-824
5. Hqp1351
6. Olverembatinib [usan]
7. Hqp-1351
8. Kv1m7q3cbp
9. 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
10. Chembl2316582
11. D-824
12. Gzd 824
13. Benzamide, 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-
14. Olverembatinib Dimesylate
15. Hqp1351 Dimesylate
16. Hqp-1351 Dimesylate
17. 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
18. Benzamide, 4-methyl-n-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1h-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-
19. 4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide
20. 4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1h-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide
21. Hqp1351 Free Base
22. Hqp-1351 Free Base
23. Unii-kv1m7q3cbp
24. Olverembatinib [inn]
25. Schembl3424528
26. Olverembatinib [who-dd]
27. Gtpl10630
28. Ex-a829
29. Bcp07502
30. Bdbm50425780
31. Who 11221
32. Zinc95594040
33. Akos026750647
34. Cs-1444
35. Sb16617
36. Compound 10a [pmid: 23301703]
37. Ncgc00351607-06
38. Ac-35436
39. As-75170
40. Hy-15666
41. Ft-0700150
42. A16264
43. C72036
44. A899056
45. J-690110
| Molecular Weight | 532.6 g/mol |
|---|---|
| Molecular Formula | C29H27F3N6O |
| XLogP3 | 4.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 532.21984399 g/mol |
| Monoisotopic Mass | 532.21984399 g/mol |
| Topological Polar Surface Area | 77.2 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 910 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Olverembatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olverembatinib, including repackagers and relabelers. The FDA regulates Olverembatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olverembatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Olverembatinib supplier is an individual or a company that provides Olverembatinib active pharmaceutical ingredient (API) or Olverembatinib finished formulations upon request. The Olverembatinib suppliers may include Olverembatinib API manufacturers, exporters, distributors and traders.
Olverembatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olverembatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olverembatinib GMP manufacturer or Olverembatinib GMP API supplier for your needs.
A Olverembatinib CoA (Certificate of Analysis) is a formal document that attests to Olverembatinib's compliance with Olverembatinib specifications and serves as a tool for batch-level quality control.
Olverembatinib CoA mostly includes findings from lab analyses of a specific batch. For each Olverembatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olverembatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olverembatinib EP), Olverembatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olverembatinib USP).
LOOKING FOR A SUPPLIER?
